Want to see AU:CBL full AI Analyst Report?
CBL Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.10
Previous CloseN/A
Volume65.91K
Average Volume (3M)173.99K
Market Cap
AU$30.49M
Enterprise ValueAU$25.95M
Total Cash (Recent Filing)AU$3.06M
Total Debt (Recent Filing)AU$258.10K
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding441,897,670
10 Day Avg. Volume327,267
30 Day Avg. Volume173,987
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.44
Price to Sales (P/S)1.29
P/FCF Ratio-1.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Top-line Revenue GrowthSustained ~16% revenue growth indicates steady demand for the company's assistive-technology products and growing market adoption. Over the next 2–6 months this trend supports scaling opportunities, improving leverage on fixed costs, and validates product-market fit in a niche medical devices segment.
Conservative Leverage / Strong Equity BaseA conservative capital structure with low leverage preserves financial flexibility when operating cash flow is weak. This reduces near-term refinancing risk and gives management optionality to fund R&D, commercial expansion, or bridge financing without immediate solvency pressure over the coming months.
Healthy Gross Profit MarginsHealthy gross margins imply viable unit economics and pricing power for core products. If management controls operating expenses, these margins provide a clear pathway to improving operating profitability over time as revenue scales and fixed costs are absorbed.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow indicates the business is not generating sufficient cash from operations, increasing reliance on external funding. Over a 2–6 month horizon this raises liquidity and execution risk, potentially constraining marketing, R&D, and go-to-market investment.
Ongoing Net Losses And Weak ProfitabilityConsistent net losses and negative EBIT margins mean the company is not yet converting revenue into operating profits. This undermines retained earnings, limits reinvestment capacity, and makes sustained scaling dependent on either margin improvement or continued external capital.
Negative Return On EquityNegative ROE signals that deployed capital has not generated shareholder value. Over the medium term this can impair investor confidence and raise the cost or reduce availability of equity financing, making it harder to fund growth or cover operating shortfalls.
Control Bionics Ltd. News
CBL FAQ
What was Control Bionics Ltd.’s price range in the past 12 months?
Control Bionics Ltd. lowest share price was AU$0.03 and its highest was AU$0.10 in the past 12 months.
What is Control Bionics Ltd.’s market cap?
Control Bionics Ltd.’s market cap is AU$30.49M.
When is Control Bionics Ltd.’s upcoming earnings report date?
Control Bionics Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 36 days.
How were Control Bionics Ltd.’s earnings last quarter?
Control Bionics Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is Control Bionics Ltd. overvalued?
According to Wall Street analysts Control Bionics Ltd.’s price is currently Overvalued.
Does Control Bionics Ltd. pay dividends?
Control Bionics Ltd. does not currently pay dividends.
What is Control Bionics Ltd.’s EPS estimate?
Control Bionics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Control Bionics Ltd. have?
Control Bionics Ltd. has 441,897,670 shares outstanding.
What happened to Control Bionics Ltd.’s price movement after its last earnings report?
Control Bionics Ltd. reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Control Bionics Ltd.?
Currently, no hedge funds are holding shares in AU:CBL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Control Bionics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CBL Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth AU$30.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.36%
Trailing 12-Months
Company Description
Control Bionics Ltd.
Operating in Australia and North America, Control Bionics Limited and its subsidiaries specialize in the innovation, development, and market introduction of sophisticated assistive communication technologies. The company's offerings include the NeuroNode Trilogy and NeuroNode3 systems, which empower individuals facing speech and mobility challenges to control computers for speech generation, electronic correspondence, leisure activities, and remote operation of other devices. Control Bionics also provides Cosmos Connect, a versatile interface capable of managing diverse equipment like wheelchairs, robotic dining aids, and gaming consoles. Additionally, they offer Uno Touch, a dedicated speech-generating device, alongside various other sensors for a broad spectrum of uses. Founded in 2005, the entity was initially named Control Bionics Holdings Pty Limited before rebranding as Control Bionics Limited in September 2020. The company's base of operations is situated in Camberwell, Australia.
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Compumedics Limited
―
Neurotech International
―
EMvision Medical Devices Ltd.
―